Radiomic–Molecular Profiles for Individualized Care

Abstract

Precision medicine continues to evolve with the integration of radiomics and molecular profiling, offering unprecedented potential for individualized care. By extracting large sets of quantitative features from medical images and linking them to underlying molecular alterations, radiomic–molecular profiles provide a comprehensive view of disease biology. This review synthesizes current evidence on the clinical application, underlying mechanisms, and practical implications of integrating radiomic and molecular data in patient management. We discuss the epidemiology of target diseases, pathophysiological foundations, risk stratification, diagnostic advancements, management strategies, emerging therapies, and up-to-date guideline recommendations, emphasizing the transformative impact on personalized healthcare.

Introduction

The convergence of radiomics and molecular profiling represents a paradigm shift in personalized medicine. Radiomics, the high-throughput extraction of quantitative features from medical imaging, enables the characterization of tissue heterogeneity and subtle phenotypic differences. When combined with molecular profiles—encompassing genomics, transcriptomics, proteomics, and metabolomics—clinicians can obtain a multidimensional understanding of disease states. This integrative approach facilitates refined risk stratification, early diagnosis, and tailored therapeutic strategies, moving beyond traditional population-based protocols towards truly individualized care. Recent advances in computational methods, machine learning, and data integration are accelerating the adoption of radiomic–molecular profiling in oncology, neurology, cardiology, and other specialties.

Epidemiology / Disease Burden

Radiomic–molecular profiling is most advanced in oncology, where the global burden of cancer persists as a leading cause of morbidity and mortality. Despite progress in screening and treatment, heterogeneity within and between tumors continues to challenge clinical outcomes. For example, lung and breast cancers—among the most prevalent worldwide—display significant molecular and phenotypic diversity. Traditional histopathological classifications often fail to capture this complexity, leading to variable responses and outcomes. Integrating radiomic and molecular data addresses these gaps, offering improved prognostication and therapeutic alignment. This approach is expanding to other diseases with considerable heterogeneity, such as gliomas, liver diseases, and chronic inflammatory conditions, reflecting its growing clinical relevance.

Pathophysiology

The pathophysiological basis of radiomic–molecular profiling lies in the interplay between genetic, epigenetic, and microenvironmental factors that drive disease progression and phenotypic expression. Molecular alterations—including mutations, copy number variations, and gene expression changes—manifest as distinct imaging phenotypes due to their influence on cellular architecture, angiogenesis, and metabolic activity. Radiomic analysis quantifies these imaging characteristics, such as texture, shape, intensity, and spatial relationships, providing surrogate markers of underlying biology. Integrative analysis can reveal correlations between specific radiomic features and driver mutations, immune microenvironment, or hypoxic status, supporting both mechanistic understanding and clinical translation.

Risk Factors

Risk stratification is enhanced through radiomic–molecular integration, as traditional clinical risk factors (age, sex, smoking status, comorbidities) are complemented by imaging and molecular signatures. For example, in lung cancer, radiomic features may predict the likelihood of EGFR mutations or ALK rearrangements, informing targeted therapy eligibility. In glioblastoma, combined radiomic and genetic markers refine prognostic models beyond clinical staging. By capturing both inherited and acquired risk factors at multiple biological scales, clinicians can offer more precise surveillance, early intervention, and risk-matched therapies.

Clinical Features

Radiomic–molecular profiling aids in characterizing the clinical features and phenotypic heterogeneity of various diseases. In cancer, this approach distinguishes between indolent and aggressive lesions, predicts metastatic potential, and identifies early recurrence. In neurodegenerative disorders, radiomic features extracted from MRI may correlate with molecular biomarkers of disease progression, such as amyloid or tau levels in Alzheimer’s disease. The ability to non-invasively assess disease activity and response to therapy enhances clinical decision-making and patient engagement.

Diagnosis

Diagnostic accuracy is significantly improved by integrating radiomic and molecular data. Advanced machine learning algorithms can analyze complex datasets to differentiate benign from malignant lesions, subclassify tumors, and predict molecular subtypes with high sensitivity and specificity. For instance, in non-small cell lung cancer, radiomic signatures from CT scans can predict PD-L1 expression, facilitating immunotherapy decisions without the need for repeated biopsies. In breast cancer, multiparametric MRI radiomics combined with gene expression profiles enhances molecular subtype classification. These advances support earlier, less invasive, and more accurate diagnoses across multiple specialties.

Treatment & Management

Personalized treatment planning is a cornerstone of radiomic–molecular profiling. By predicting therapeutic response and toxicity risk, clinicians can tailor interventions to maximize efficacy and minimize harm. For example, in head and neck cancers, radiomic–molecular models forecast response to chemoradiation, guiding organ-preserving strategies. In hepatocellular carcinoma, combined radiomic and genomic features inform the choice between surgical resection, ablation, or systemic therapy. Integration with electronic health records and clinical decision support tools streamlines workflow and supports multidisciplinary care.

Recent Advances / Emerging Therapies

Recent years have witnessed remarkable advances in radiomic–molecular research. Deep learning and artificial intelligence facilitate feature extraction, pattern recognition, and predictive modeling at unprecedented scale and speed. Multi-omics approaches, including radiogenomics and radiotranscriptomics, enable comprehensive profiling of disease states. Liquid biopsy technologies further augment molecular characterization, allowing real-time monitoring alongside imaging. Clinically, these innovations are being incorporated into ongoing trials of adaptive therapy, immunotherapy selection, and early intervention protocols. Translational research efforts are focused on standardizing data acquisition, harmonizing protocols, validating predictive models, and integrating findings into routine practice.

Guideline Recommendations

Professional societies are increasingly recognizing the value of radiomic–molecular profiling in clinical guidelines. The American Society of Clinical Oncology and the European Society for Medical Oncology recommend molecular testing and advanced imaging for certain cancers, with ongoing updates to incorporate radiomic biomarkers. The Radiological Society of North America supports the development of standardized radiomics pipelines and reporting frameworks. Guidelines emphasize multidisciplinary collaboration, data quality, and ethical considerations, particularly regarding patient privacy and informed consent. As evidence accrues, it is anticipated that radiomic–molecular profiling will become a standard component of precision medicine protocols across specialties.

Conclusion

Radiomic–molecular profiling represents a transformative advance in individualized care, bridging the gap between imaging phenotypes and molecular pathology. By harnessing the power of big data and integrative analytics, clinicians can achieve earlier diagnosis, more accurate risk stratification, and tailored therapy selection, ultimately improving patient outcomes. Ongoing research, technological innovation, and guideline development will continue to drive adoption, with the promise of more precise, effective, and patient-centered healthcare for diverse disease states.